Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Gossamer Bio, Inc.NASDAQ: GOSS

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 41.4% from a year ago

Cash & equivalents stood at $41.03M at the end of Q1 FY2026, up 41.4% from a year earlier and up 8.7% from the prior quarter. Over 3 fiscal years it compounded at -30.4% a year.

Context

  • Cash & equivalents amounted to 31.8% of total assets at the end of Q1 FY2026, up 21.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +41.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$41.03M+8.7% QoQ
Last fiscal yearDec 2025
$37.73M-18.1% YoY
Year agoMar 2025
$29.02M+41.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.4%——
1 year-18.1%——
3-year CAGR-30.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
37.73M USD
Year-over-year change
-18.1%
4-year CAGR
-32.7%

Cash & Equivalents vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's Mar 2026 cash & equivalents of $41.03M is the 5th highest of the 9 companies compared; the peer median is $46.32M.
  • Its year-over-year change of +41.4% is the 2nd highest of 8, against a peer median of -39.4%.
  • Cash & equivalents amounts to 31.8% of total assets for GOSS, versus a peer median of 14.2%.
GOSS Competitors Peer median
Cash & Equivalents for GOSS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PRTAProthena Corporation plcMar 2026$329.46M -21.2%-24.4%94.2%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$229.34M ——68.4%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$72.49M -45.7%+4.8%14.1%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$52.55M +3.8%+26.8%9.9%
GOSSGossamer Bio, Inc.Mar 2026$41.03M +41.4%-30.4%31.8%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$40.1M +702.2%-29.7%15.8%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$38.09M -39.4%-9.5%14.2%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$24.41M -46.6%+18.4%4.8%
RGNXREGENXBIO Inc.Mar 2026$15.23M -88.3%-29.2%4.5%
Peer median (excluding GOSS) $46.32M-39.4%-9.5%14.2%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents183.4M111.97M32.11M46.07M37.73M
Short-term Investments141.82M143.71M264.32M248.44M99.2M
Net Receivables0005.34M12.53M
Inventory00000
Other Current Assets64K010.09M10.03M18.19M
Total Current Assets331.78M261.88M306.52M309.89M167.64M
Property, Plant & Equipment (Net)10.8M9.89M4.78M5.12M4.2M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.08M680K618K283K408K
Total Non-current Assets11.88M10.57M5.4M5.4M4.61M
Total Assets343.66M272.45M311.92M315.29M172.25M
Account Payables3.24M1.46M5.53M2.32M5.96M
Short-term Debt011.61M11.61M00
Tax Payables00000
Deferred Revenue00017.05M19.99M
Other Current Liabilities11.92M13.53M10.29M12M11.21M
Total Current Liabilities39.86M49.23M51.6M45.01M63.44M
Long-term Debt179.12M207.7M197.41M197.52M198.51M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00038.87M29.61M
Other Non-current Liabilities00000
Total Non-current Liabilities182.34M211.14M197.55M240.79M231.57M
Total Liabilities222.19M260.37M249.15M285.8M295.01M
Common Stock8K10K23K23K24K
Retained Earnings(811.53M)(1.03B)(1.21B)(1.27B)(1.44B)
Accumulated OCI45K(574K)(350K)1.19M(5.15M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity121.46M12.08M62.77M29.49M(122.76M)
Total Debt185.24M225.74M212.46M202.88M202.91M
Net Debt1.83M113.77M180.36M156.81M165.17M

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.